BioNTech Agrees To Pay $205 Million To Shorten A Future Cancer Drug's FDA Review

The voucher would cover one application from its late-stage oncology pipeline, while Comirnaty remains its one marketed product.

Share
BioNTech Agrees To Pay $205 Million To Shorten A Future Cancer Drug's FDA Review

BioNTech, which develops immunotherapies for cancer and other serious diseases, agreed Tuesday to pay $205 million in cash for a voucher that shortens the FDA's target review of one drug application. The company said in a statement that it intends to use the voucher for a future application from its late-stage cancer-treatment pipeline.

A Shorter Route Through FDA Review

Scholar Rock is selling the priority review voucher to BioNTech. The voucher gives one application priority review at the U.S. Food and Drug Administration, reducing the agency's target review period and potentially bringing an approval forward.

BioNTech has agreed to the purchase; completion still requires U.S. antitrust clearance. Its intended use is a future submission, so the benefit concerns the regulatory review stage of a cancer treatment's development.

The $205 million purchase buys that review mechanism rather than a treatment from Scholar Rock. BioNTech plans to apply it to a medicine in its own late-stage oncology pipeline.

Cancer Development Beyond Comirnaty

The planned purchase fits BioNTech's main business focus: oncology. The Mainz, Germany-based company's cancer pipeline has 16 clinical programs, with work spanning mRNA cancer immunotherapies, targeted antibodies and antibody-drug conjugates — treatments that pair an antibody with a drug.

Those development programs sit alongside a commercial business centered on Comirnaty, the COVID-19 vaccine BioNTech sells with Pfizer. Comirnaty is BioNTech's one marketed product, while the voucher is intended for a cancer medicine still in development.

As of March 2026, BioNTech's COVID-19 vaccines had authorization or approval in more than 180 countries and regions, and shipments exceeded 5 billion doses. Pfizer holds worldwide marketing and distribution rights apart from Greater China, Germany and Türkiye.

BioNTech holds those rights in Germany and Türkiye. Fosun Pharma holds them in Mainland China, Hong Kong, Macau and Taiwan.

For BioNTech's cancer pipeline, the proposed purchase offers a shorter target review for one future application, with the prospect of an earlier approval.

Sources

More on BioNTech

All BioNTech (BNTX) coverage →